FDA declines to approve Valeant’s plaque psoriasis treatment

Share this post

(Reuters) – Canada-based Valeant Pharmaceuticals International said on Monday that U.S. health regulators had declined to approve its lotion to treat plaque psoriasis, citing questions related to certain data.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply